Clinical Trials Logo

Neoplasms, Second Primary clinical trials

View clinical trials related to Neoplasms, Second Primary.

Filter by:
  • Recruiting  
  • « Prev · Page 14

NCT ID: NCT01348256 Recruiting - Clinical trials for Colorectal Carcinoma

Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma

Start date: November 2010
Phase: Phase 2
Study type: Interventional

In this randomized multicentric phase II study, patients with colorectal carcinoma with resectable hepatic metastasis will be randomized to treatment with dendritic cells or to observation, following conventional treatment with surgery and chemotherapy.

NCT ID: NCT01050504 Recruiting - Clinical trials for Malignant Solid Neoplasm

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Start date: August 2009
Phase:
Study type: Observational

This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.

NCT ID: NCT00406900 Recruiting - Melanoma Clinical Trials

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

Start date: January 1999
Phase: N/A
Study type: Observational

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients